Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
about
Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expressionEndoglin (CD105) as a urinary and serum marker of prostate cancerHigher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistanceImmunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAFCirculating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancersExpression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissueA prostate cancer model build by a novel SVM-ID3 hybrid feature selection method using both genotyping and phenotype data from dbGaP.Detection and cloning of a protein recognized by anti-human prostate-specific antigen (PSA) antibody in the rat ventral prostate.Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach.Screening for prostate cancer.Vaccines as monotherapy and in combination therapy for prostate cancer.Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments.Selenium-responsive proteins in the sera of selenium-enriched yeast-supplemented healthy African American and Caucasian menNoncoding RNAs as novel biomarkers in prostate cancer.Dendritic cell-based immunotherapy for prostate cancer.Prostate-specific antigen kallikrein and the heartIdentification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.Initial biopsy outcome prediction in Korean patients-comparison of a noble web-based Korean prostate cancer risk calculator versus prostate-specific antigen testing.Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study.Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.Serum total PSA and free PSA in breast tumors.Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markersCurated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer.Prostate Cancer Can Be Detected Even in Patients with Decreased PSA Less than 2.5 ng/ml after Treatment of Chronic Prostatitis.Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.Acute onset-low back pain and hip pain secondary to metastatic prostate cancer: a case report.Portable and quantitative detection of protein biomarkers and small molecular toxins using antibodies and ubiquitous personal glucose metersProstate-specific antigen in serum of women with breast cancerFifth-generation digital immunoassay for prostate-specific antigen by single molecule array technologyProstate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumoursAntigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.Role of prostate-specific antigen change ratio at initial biopsy as a novel decision-making marker for repeat prostate biopsy.Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.Early detection of prostate cancer. Role of prostate-specific antigenSipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.The value of serum alpha-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy.Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly.Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.
P2860
Q22009031-142EC51D-930A-4CDC-AB3E-A8E924EA4CEBQ24314256-EF39B9ED-A12D-4FE2-B3F8-F5BD4E02C952Q24642804-E6A19D89-47A1-4D00-A149-8D868FA0BD41Q24645388-8A3D982E-C36B-4B70-A02A-7A69C02F7160Q24815893-0C37024E-24C7-438A-9E3E-CD17FF14A124Q27694500-276223BD-8136-4C5E-B493-ACDA2F3B1FE9Q28344337-DDA4422E-999F-4109-B881-183FB44D6A4AQ30782001-73EDE750-69EB-4AB1-8361-C5134B29058BQ31953978-F10F6992-2244-4F42-B74A-BD0100626F3AQ33258849-E884CC6F-9AA6-4EA0-8B4C-0137D5A52FACQ33608384-EBA8F92C-7BEA-4BFA-8BFB-1F48845C2CA7Q34039068-876BB1D5-1609-4ED2-AA32-0B9DC2D5B616Q34122725-3F7BA65F-1401-4418-BDB5-981EBA1CFDDDQ34126917-F26572AF-2E96-457F-B125-FE4D6B60DC6CQ34176890-C3ADBC3C-ED21-43BF-AB66-3916A2C189C6Q34284652-950BE693-32D0-4504-AB62-44E3098E9F24Q34390618-1CD9DC24-D18F-48E8-A0E1-63331BBCD513Q34429991-1B575E1D-BD49-441F-A1E0-43BBF8229FEFQ34451940-671E806B-4AA7-45AB-8198-7B7FCDE814EFQ34555221-BF758EA9-DF64-422B-8B49-EFFE02C20B3FQ34680813-48DD8A7B-1FCB-43E3-8E08-DB1EE669E09BQ35022387-ABB0688D-98D4-437E-9F12-0D0EE6E35791Q35032198-BC8314AC-71F1-471A-8EA8-363C6D94A8D7Q35140145-40674766-9BE7-46B8-9C8B-A50E7BB25242Q35151989-DBFB0E95-4676-4D75-B2AF-602F17CF18F9Q35179361-53638FB4-A949-4158-A773-4E347EA0A008Q35729693-69814CC6-88B7-4282-A039-E9065804BCC5Q35926118-9E2D1AD1-8CA1-4990-87AC-568D8A7FFCB4Q36081111-E71B6A21-34A8-4A45-8583-C3B7A4BD0DA1Q36108451-3D3F1B66-18C9-4EF7-BD77-9AE72E57295CQ36115207-A77A9F06-1875-403C-91AF-FE295E87F785Q36116415-6A3B3F84-A820-4347-B854-79B32D1E0275Q36120412-241631F9-BBD7-4608-A45B-F6517D16818AQ36254081-79145D9F-4EB4-4C38-A098-5C7CF77AE4CFQ36284979-F8218C8F-93DB-49C3-9202-4DAE0D747E1DQ36285594-B7D16E38-EEBE-4D9E-A90B-7BEA939D338BQ36292222-29467760-1FC3-407E-AC91-E9A83975E652Q36326737-2B660BC7-FF33-4926-9F85-4E12D97A2007Q36410718-66FF55D3-5809-402D-80C4-589B1649292EQ36414352-7FF5331C-A9E1-4400-851D-199110166E16
P2860
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Prostate specific antigen: a c ...... denocarcinoma of the prostate.
@ast
Prostate specific antigen: a c ...... denocarcinoma of the prostate.
@en
type
label
Prostate specific antigen: a c ...... denocarcinoma of the prostate.
@ast
Prostate specific antigen: a c ...... denocarcinoma of the prostate.
@en
prefLabel
Prostate specific antigen: a c ...... denocarcinoma of the prostate.
@ast
Prostate specific antigen: a c ...... denocarcinoma of the prostate.
@en
P1476
Prostate specific antigen: a c ...... denocarcinoma of the prostate.
@en
P2093
Oesterling JE
P304
P407
P577
1991-05-01T00:00:00Z